The effect of lowering blood pressure by magnesium supplementation in diabetic hypertensive adults with low serum magnesium levels: A randomized, double-blind, placebo-controlled clinical trial

Journal of Human Hypertension

Volumn 23, Issue 4, 2009, Pages 245-251

  Guerrero Romero, F ^a   Rodriguez Moran M ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; FIBRIC ACID DERIVATIVE; GLIBENCLAMIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM; MAGNESIUM CHLORIDE; PLACEBO; PRAVASTATIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE VARIABILITY; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC HYPERTENSION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOMAGNESEMIA; LIFESTYLE MODIFICATION; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

ADULT; AGED; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; MAGNESIUM CHLORIDE; MALE; MIDDLE AGED;

EID: 63349092570     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2008.129     Document Type: Article

References (45)

1. Barbagallo M, Dominguez LJ. Magnesium metabolism in type 2 diabetes mellitus, metabolic syndrome and insulin resistance. Arch Biochem Biophys 2007; 458: 40-47.
2. Paolisso G, Scheen A, D'Onofrio F, Lefèbvre P. Magnesium and glucose homeostasis. Diabetologia 1990; 33: 511-514.
3. Barbagallo M, Dominguez LJ, Resnick LM. Magnesium metabolism in hypertension and type 2 diabetes mellitus. Am J Ther 2007; 14 375-385.
4. Guerrero-Romero F, Rodríguez-Morán M. Complementary therapies for diabetes: The case for chromium, magnesium, and antioxidants. Arch Med Res 2005; 36: 250-257.
5. Altura BM, Altura BT. Role of magnesium in the pathogenesis of hypertension updated: Relationship to its actions on cardiac, vascular smooth muscle, and endothelial cells. In: Laragh JH, Brenner BM (eds.). Hypertension: Pathophysiology, Diagnosis, and Management, 2nd edn, Raven Press: New York, NY, 1995, pp 1213-1242.
6. Altura BM, Altura BT. Magnesium ions and contraction of vascular smooth muscles: Relationship to some vascular diseases. Fed Proc 1981; 40: 2672-2679.
7. Joffres MR, Reed DM, Yano K. Relationship of magnesium intake and other dietary factors to blood pressure: The Honolulu heart study. Am J Clin Nutr 1987; 45: 469-475.
8. Ascherio A, Hennekens Ch, Willett WC, Sacks F, Rosner B, Manson J et al. Prospective study of nutritional factors, blood pressure, and hypertension among US women. Hypertension 1996; 27: 1065-1072.
9. Motoyama T, Sano H, Fukuzaky H. Oral magnesium supplementation in patients with essential hypertension. Hypertension 1989; 13: 227-232.
10. Witteman JC, Grobbee DE, Derkx FH, Bouillon R, de Bruijn AM, Hofman A. Reduction of blood pressure with oral magnesium supplementation in women with mild to moderate hypertension. Am J Clin Nutr 1994; 60: 129-135.
11. Yokota K, Kato M, Lister F, Ii H, Hayakawa T, Kikuta T et al. Clinical efficacy of magnesium supplementation in patients with type 2 diabetes. J Am Coll Nutr 2004; 23: 506S-509S.
12. Kawano Y, Matsuoka H, Takishita S, Omae T. Effects of magnesium supplementation in hypertensive patients: Assessment by office, home, and ambulatory blood pressures. Hypertension 1998; 32: 260-265.
13. Ferrara LA, Iannuzzi R, Castaldo A, Iannuzzi A, Dello Russo A, Mancini M. Long-term magnesium supplementation in essential hypertension. Cardiology 1992; 81: 25-33.
14. Cappuccio FP, Markandu ND, Beynon GW, Shore AC, Sampson B, MacGregor GA. Lack of effect of oral magnesium on high blood pressure: A double blind study. Br Med J (Clin Res Ed) 1985; 291(6490): 235-238.
15. Zemel PC, Zemel MB, Urberg M, Douglas FL, Geiser R, Sowers JR. Metabolic and hemodynamic effects of magnesium supplementation in patients with essential hypertension. Am J Clin Nutr 1990; 51: 665-669.
16. Pham PC, Pham PM, Pham SV, Miller JM, Pham PT. Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol 2007; 2 366-373.
17. Altura BM, Altura BT, Gebrewold A, Ising H, Günther T. Magnesium deficiency and hypertension: Correlation between magnesium-deficient diets and microcirculatory changes in situ. Science 1984; 223 1315-1317.
18. Moher D, Schulz KF, Altman DG. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 2001; 134: 657-662.
19. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D et al The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 134: 663-694.
20. Guerrero-Romero F, Rodrǵuez-Morán M. Relationship between serum magnesium levels and C-reactive protein concentration, in non-diabetic, non-hypertensive obese subjects. Int J Obes Relat Metab Disord 2002; 26: 469-474.
21. Firoz M, Graber M. Bioavailability of US comercial magnesium preparations. Magnes Res 2001; 14: 257-262.
22. Laires MJ, Moreira H, Monteiro CP, Sardinha L, Limaão F, Veiga L et al. Magnesium, insulin resistance and body composition in healthy postmenopausal women. J Am Coll Nutr 2004; 23: 510S-513S.
23. Ford ES, Mokdad AH. Dietary magnesium intake in a national sample of US adults. J Nutr 2003; 133: 2879-2882.
24. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. The National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
25. Altura BM, Altura BT. Interactions of Mg and K on blood vessels - aspects in view of hypertension. Review of present status and new findings. Magnesium 1984; 3: 175-194.
26. + movements. Can J Physiol Pharmacol 1982; 60: 459-482.
27. + versus organic calcium channel blockers on myogenic tone and agonist-induced responsiveness of blood vessels. Can J Physiol Pharmacol 1987; 654: 729-745.
28. Stephenson EW, Podolsky RJ. Regulation by magnesium of intracellular calcium movement in skinned muscle fibers. J Gen Physiol 1977; 69: 1-16.
29. Touyz RM. Transient receptor potential melastatin 6 and 7 channels, magnesium transport and vascular biology: Implications in hypertension. Am J Physiol Heart Circ Physiol 2008; 294(3): H1103-H1118.
30. Jee SH, Miller III ER, Guallar E, Singh VK, Appel LJ, Klag MJ. The effect of magnesium supplementation on blood pressure: A meta-analysis of randomized clinical trials. Am J Hypertens 2002; 15: 691-696.
31. Kawasaki T, Itoh K, Kawasaki M. Reduction in blood pressure with a sodium-reduced, potassium- and magnesium-enriched mineral salt in subjects with mild essential hypertension. Hypertens Res 1998; 21: 235-243.
32. Shafique M, Misbah-ul-Ain, Ashraf M. Role of magnesium in the management of hypertension. J Pak Med Assoc 1993; 43: 77-78.
33. Atarashi K, Takagi M, Matsuoka H, Sugimoto T. Effects of magnesium on changes in blood pressure and plasma aldosterone induced by angiotensin II. Am J Hypertens 1990; 3(6 Part 1): 488-490.
34. Shimosawa T, Takano K, Ando K, Fujita T. Magnesium inhibits norepinephrine release by blocking N-type calcium channels at peripheral sympathetic nerve endings. Hypertension 2004; 44: 897-902.
35. Lind L, Lithell H, Pollare T, Ljunghall S. Blood pressure response during long-term treatment with magnesium is dependent on magnesium status. A double-blind, placebo-controlled study in essential hypertension and in subjects with high-normal blood pressure. Am J Hypertens 1991; 4: 674-679.
36. Barbagallo M, Dominguez LJ, Resnick LM. Protective effects of captopril against ischemic stress: Role of cellular Mg. Hypertension 1999; 34(4 Part 2): 958-963.
37. Motoyama T, Sano H, Fukuzaki H. Oral magnesium supplementation in patients with essential hypertension. Hypertension 1989; 13: 227-232.
38. Liao D, Arnett DK, Tyroler HA, Riley WA, Chambless LE, Szklo M et al Arterial stiffness and the development of hypertension. The ARIC study. Hypertension 1999; 34: 201-206.
39. Salomaa V, Riley W, Kark JD, Nardo C, Folsom AR. Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation 1995; 91 1432-1443.
40. Trials of Hypertension Prevention Collaborative Research Group. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I. JAMA 1992; 267: 1213-1220.
41. Reinhart R, Marx J, Haas R, Desbiens N. Intracellular magnesium of mononuclear cells from venous blood of clinical healthy subjects. Clin Chim Acta 1988; 48: 2415-2420.
42. Zanella MT, Kohlmann Jr O, Ribeiro AB. Treatment of obesity, hypertension, and diabetes syndrome. Hypertension 2001; 38: 705-708.
43. Snow V, Weiss KB, Mottur-Pilson C, Clinical Efficacy Assessment Subcommittee of the American College of Physicians. The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus. Ann Intern Med 2003; 138: 587-592.
44. Zanella MT, Plavnik FL, Kohlmann Jr O, Ribeiro AB. Hypokalemia, glucose intolerance and hyperinsulinemia during diuretic therapy. Hypertension 1992; 19(Supp II): II-26-II-29.
45. Pham PC, Pham PM, Pham SV, Miller JM, Pham PT. Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol 2007; 2 366-373.